{"title":"免疫检查点抑制剂引起的皮肤毒性对患者生活质量的影响以及皮肤病干预的作用。","authors":"Christina Kemanetzi, Konstantinos Lallas, Elizavet Lazaridou, Chrysoula Papageorgiou, Aimilios Lallas, Alexandros Stratigos, Eleni Timotheadou, George Lazaridis, Dimitrios Dionysopoulos, Kalliopi Kalaitzi, Antonios Tsimpidakis, Myrto Trakatelli, Aikaterini Patsatsi, Vasiliki Nikolao, Zoe Apalla","doi":"10.5826/dpc.1403a118","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Data regarding quality of life (QoL) of oncologic patients experiencing dermatologic immune-related adverse events (dirAEs) and their course after dermatologic intervention are scarce.</p><p><strong>Objectives: </strong>To assess the impact of dirAEs on patients QoL and to investigate the correlation between dermatologic and oncologic indexes used for estimating QoL.</p><p><strong>Methods: </strong>We enrolled oncologic patients with dirAEs managed in two supportive onco-dermatology outpatient clinics in Greece. Patient-reported outcomes included DLQI, EORTC-QLQ-C30 and Numerical Rating Scale for pruritus (pNRS).</p><p><strong>Results: </strong>Overall, 110 patients were enrolled in the study. Mean (standard deviation) DLQI and pNRS scores were 15.54 (5.44) and 7.25 (2.95), correspondingly, while functional, symptom and summary scores of EORTC-C30 were 79.17 (2.11), 17.66 (3.60) and 80.67 (3.08), respectively. After therapeutic interventions, there was a statistically significant decrease in DLQI scores after first intervention compared to baseline, and second intervention compared to first (mean decrease 4.38 (2.91), P < 0.001 and 5.16 (3.99), P < 0.001, respectively). DLQI showed no correlation with global health status/QoLs (rho 0.01, P = 0.90) of EORTC-C30.</p><p><strong>Conclusions: </strong>DirAEs negatively affect QoL. Dermatologic intervention improves patients QoL, facilitating an unimpaired oncologic treatment. Poor correlation between DLQI and EORTC-QLQ-30 highlights the need for adapted QoL measurement tools in the context of immune checkpoint inhibitors treatment.</p>","PeriodicalId":11168,"journal":{"name":"Dermatology practical & conceptual","volume":"14 3","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11314511/pdf/","citationCount":"0","resultStr":"{\"title\":\"The Impact of Immune Checkpoint Inhibitors-Induced Skin Toxicity on Patients Quality of Life and the Role of Dermatologic Intervention.\",\"authors\":\"Christina Kemanetzi, Konstantinos Lallas, Elizavet Lazaridou, Chrysoula Papageorgiou, Aimilios Lallas, Alexandros Stratigos, Eleni Timotheadou, George Lazaridis, Dimitrios Dionysopoulos, Kalliopi Kalaitzi, Antonios Tsimpidakis, Myrto Trakatelli, Aikaterini Patsatsi, Vasiliki Nikolao, Zoe Apalla\",\"doi\":\"10.5826/dpc.1403a118\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Data regarding quality of life (QoL) of oncologic patients experiencing dermatologic immune-related adverse events (dirAEs) and their course after dermatologic intervention are scarce.</p><p><strong>Objectives: </strong>To assess the impact of dirAEs on patients QoL and to investigate the correlation between dermatologic and oncologic indexes used for estimating QoL.</p><p><strong>Methods: </strong>We enrolled oncologic patients with dirAEs managed in two supportive onco-dermatology outpatient clinics in Greece. Patient-reported outcomes included DLQI, EORTC-QLQ-C30 and Numerical Rating Scale for pruritus (pNRS).</p><p><strong>Results: </strong>Overall, 110 patients were enrolled in the study. Mean (standard deviation) DLQI and pNRS scores were 15.54 (5.44) and 7.25 (2.95), correspondingly, while functional, symptom and summary scores of EORTC-C30 were 79.17 (2.11), 17.66 (3.60) and 80.67 (3.08), respectively. After therapeutic interventions, there was a statistically significant decrease in DLQI scores after first intervention compared to baseline, and second intervention compared to first (mean decrease 4.38 (2.91), P < 0.001 and 5.16 (3.99), P < 0.001, respectively). DLQI showed no correlation with global health status/QoLs (rho 0.01, P = 0.90) of EORTC-C30.</p><p><strong>Conclusions: </strong>DirAEs negatively affect QoL. Dermatologic intervention improves patients QoL, facilitating an unimpaired oncologic treatment. Poor correlation between DLQI and EORTC-QLQ-30 highlights the need for adapted QoL measurement tools in the context of immune checkpoint inhibitors treatment.</p>\",\"PeriodicalId\":11168,\"journal\":{\"name\":\"Dermatology practical & conceptual\",\"volume\":\"14 3\",\"pages\":\"\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11314511/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatology practical & conceptual\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5826/dpc.1403a118\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology practical & conceptual","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5826/dpc.1403a118","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
简介：有关肿瘤患者皮肤科免疫相关不良事件（dirAEs）的生活质量（QoL）及其在皮肤科干预后的过程的数据很少：有关发生皮肤免疫相关不良事件（dirAEs）的肿瘤患者的生活质量（QoL）及其在皮肤病干预后的病程的数据很少：评估 dirAEs 对患者 QoL 的影响，并研究用于估算 QoL 的皮肤科和肿瘤科指标之间的相关性：我们招募了在希腊两家支持性皮肤病门诊接受治疗的dirAEs肿瘤患者。患者报告的结果包括 DLQI、EORTC-QQLQ-C30 和瘙痒症数字评定量表（pNRS）：结果：共有 110 名患者参与研究。DLQI和pNRS的平均分（标准差）分别为15.54（5.44）和7.25（2.95），而EORTC-C30的功能分、症状分和总分分别为79.17（2.11）、17.66（3.60）和80.67（3.08）。经过治疗干预后，与基线相比，第一次干预后的 DLQI 分数有显著下降，与第一次干预相比，第二次干预后的 DLQI 分数有显著下降（分别为平均下降 4.38 (2.91)，P < 0.001 和 5.16 (3.99)，P < 0.001）。DLQI 与 EORTC-C30 的总体健康状况/QoLs 没有相关性（rho 0.01，P = 0.90）：结论：DirAEs 对 QoL 有负面影响。结论：DirAEs 对 QoL 有负面影响，皮肤科干预可改善患者的 QoL，促进肿瘤治疗的顺利进行。DLQI与EORTC-QLQ-30之间的相关性较差，这凸显了在免疫检查点抑制剂治疗中对QoL测量工具进行调整的必要性。
The Impact of Immune Checkpoint Inhibitors-Induced Skin Toxicity on Patients Quality of Life and the Role of Dermatologic Intervention.
Introduction: Data regarding quality of life (QoL) of oncologic patients experiencing dermatologic immune-related adverse events (dirAEs) and their course after dermatologic intervention are scarce.
Objectives: To assess the impact of dirAEs on patients QoL and to investigate the correlation between dermatologic and oncologic indexes used for estimating QoL.
Methods: We enrolled oncologic patients with dirAEs managed in two supportive onco-dermatology outpatient clinics in Greece. Patient-reported outcomes included DLQI, EORTC-QLQ-C30 and Numerical Rating Scale for pruritus (pNRS).
Results: Overall, 110 patients were enrolled in the study. Mean (standard deviation) DLQI and pNRS scores were 15.54 (5.44) and 7.25 (2.95), correspondingly, while functional, symptom and summary scores of EORTC-C30 were 79.17 (2.11), 17.66 (3.60) and 80.67 (3.08), respectively. After therapeutic interventions, there was a statistically significant decrease in DLQI scores after first intervention compared to baseline, and second intervention compared to first (mean decrease 4.38 (2.91), P < 0.001 and 5.16 (3.99), P < 0.001, respectively). DLQI showed no correlation with global health status/QoLs (rho 0.01, P = 0.90) of EORTC-C30.
Conclusions: DirAEs negatively affect QoL. Dermatologic intervention improves patients QoL, facilitating an unimpaired oncologic treatment. Poor correlation between DLQI and EORTC-QLQ-30 highlights the need for adapted QoL measurement tools in the context of immune checkpoint inhibitors treatment.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
